TWT-202
Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine or Decitabine in Patients With AML, MDS or CMML
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 72 patients (estimated)
- Sponsors
- Treadwell Therapeutics, Inc
- Tags
- Antimetabolites, Chemotherapy, Hypomethylating Agents (HMA), PLK4 Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1566
- NCT Identifier
- NCT04730258
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.